Belumosudil, the drug shown to have the highest affinity for ILK in drug docking, is an FDA-approved drug for use against graft-versus-host disease and is known to target the polymerization of G-actin fibrils and inhibit the Rho-ROCK-MRTF pathway [71]. This evidence concerns the gene ILK and graft versus host disease.